AMENDED AND RESTATED DEPOSIT AGREEMENT by and among GENMAB A/S AND DEUTSCHE BANK TRUST COMPANY AMERICAS as Depositary, AND THE HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES EVIDENCED BY AMERICAN DEPOSITARY RECEIPTS ISSUED HEREUNDER Dated...Deposit Agreement • May 28th, 2019 • Genmab a/S • Pharmaceutical preparations • New York
DEPOSIT AGREEMENT, dated as of , 2019, by and among (i) Genmab A/S, a company incorporated under the laws of the Kingdom of Denmark, and its successors (the “Company”), (ii) Deutsche Bank Trust Company Americas, an indirect wholly owned subsidiary of Deutsche Bank A.G., acting in its capacity as depositary, and any successor depositary hereunder (the “Depositary”), and (iii) all Holders and Beneficial Owners of American Depositary Shares evidenced by American Depositary Receipts issued hereunder (all such capitalized terms as hereinafter defined).
AMENDMENT NO. 5 TO CO-DEVELOPMENT AND COLLABORATION AGREEMENTCo-Development and Collaboration Agreement • May 28th, 2019 • Genmab a/S • Pharmaceutical preparations
This Amendment No. 5 (this “Amendment No. 5”) to the Current Agreement (as defined below) is made as of January 22, 2018 (the “Amendment Effective Date”)
Execution CopyLicense Agreement • May 28th, 2019 • Genmab a/S • Pharmaceutical preparations
[***] Certain information in this document, marked by brackets, has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K under the Securities Act of 1933, as amended, because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed.
AMENDMENT NO. 1 TO CO-DEVELOPMENT AND COLLABORATION AGREEMENT BETWEEN GENMAB A/S AND GLAXO GROUP LIMITED DATED 19 DECEMBER 2006 (the “Agreement”)Co-Development and Collaboration Agreement • May 28th, 2019 • Genmab a/S • Pharmaceutical preparations
This amendment to the Agreement (“Amendment No. 1”) is made and entered into as of the day of , 2008 (the “Amendment Effective Date”), between
AMENDMENT NO. 3 TO CO-DEVELOPMENT AND COLLABORATION AGREEMENT BETWEEN GENMAB A/S AND GLAXO GROUP LIMITED DATED 19 DECEMBER 2006, AS AMENDED (the “Agreement”)Co-Development and Collaboration Agreement • May 28th, 2019 • Genmab a/S • Pharmaceutical preparations
This amendment to the Agreement (“Amendment No. 3”) is made and entered into as of the 1st day of July, 2010 (the “Amendment Effective Date”), between
AMENDMENT NO. 2 TO CO-DEVELOPMENT AND COLLABORATION AGREEMENT BETWEEN GENMAB A/S AND GLAXO GROUP LIMITED DATED 19 DECEMBER 2006 (the “Agreement”)Co-Development and Collaboration Agreement • May 28th, 2019 • Genmab a/S • Pharmaceutical preparations
This amendment to the Agreement (“Amendment No. 2”) is made and entered into as of the 18th day of December, 2008 (the “Amendment Effective Date”), between
ContractNovation Agreement • May 28th, 2019 • Genmab a/S • Pharmaceutical preparations
[***] Certain information in this document, marked by brackets, has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K under the Securities Act of 1933, as amended, because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed.
Execution CopyLicense Agreement • May 28th, 2019 • Genmab a/S • Pharmaceutical preparations • New York
[***] Certain information in this document, marked by brackets, has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K under the Securities Act of 1933, as amended, because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed.
Execution CopyLicense Agreement • May 28th, 2019 • Genmab a/S • Pharmaceutical preparations
[***] Certain information in this document, marked by brackets, has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K under the Securities Act of 1933, as amended, because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed.
AMENDED AND RESTATED EVALUATION AND COMMERCIALIZATION AGREEMENTEvaluation and Commercialization Agreement • May 28th, 2019 • Genmab a/S • Pharmaceutical preparations
THIS AMENDED AND RESTATED EVALUATION AND COMMERCIALIZATION AGREEMENT (the “Agreement”), entered into as of July 12, 2012 (the “Execution Date”) but effective as of February 25, 1999 (the “Effective Date”), is entered into by and between Bristol-Myers Squibb Company, a Delaware corporation with a place of business at Route 206 & Province Line Road, Princeton, NJ 08543 (“BMS”), Medarex, Inc., a New Jersey corporation and a wholly-owned subsidiary of BMS with a principal place of business at 521 Cottonwood Drive, Milpitas, CA 95035 (“Medarex, Inc.”), GenPharm International, Inc., a California corporation and a wholly-owned subsidiary of Medarex with a principal place of business at 521 Cottonwood Drive, Milpitas, CA 95035 (“GenPharm”) (all together “Medarex”), and Genmab A/S, a corporation organized and existing under the laws of Denmark, with a principal place of business at Bredgade 34, DK-1260 Copenhagen K, Denmark (“Genmab”).
AMENDMENT NO. 4 TO CO-DEVELOPMENT AND COLLABORATION AGREEMENT BETWEEN GENMAB A/S AND GLAXO GROUP LIMITED DATED 19 DECEMBER 2006, AS AMENDED (the “Agreement”)Co-Development and Collaboration Agreement • May 28th, 2019 • Genmab a/S • Pharmaceutical preparations
This amendment to the Agreement (“Amendment No. 4”) is made and entered into as of the 20th day of December, 2010 (the “Amendment Effective Date”), between
LICENSE AND COLLABORATION AGREEMENT by and between Seattle Genetics, Inc. and Genmab A/S Effective as of: October 7, 2011License and Collaboration Agreement • May 28th, 2019 • Genmab a/S • Pharmaceutical preparations • New York
SEATTLE GENETICS, INC., a Delaware corporation, having its principal place of business at 21823 30th Drive S.E., Bothell, Washington 98021 (hereinafter referred to as “SGI”)
ContractCo-Development and Collaboration Agreement • May 28th, 2019 • Genmab a/S • Pharmaceutical preparations
[***] Certain information in this document, marked by brackets, has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K under the Securities Act of 1933, as amended, because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed.
